June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Type III Intermediate Filament Overexpression in the Genesis of Corneal Fibrosis
Author Affiliations & Notes
  • Royce Mohan
    Neuroscience, University of Connecticut Health Center Health Center, Farmington, CT
  • Linda Cauley
    Immunology, University of Connecticut Health Center, Farmington, CT
  • Paola Bargagna-Mohan
    Neuroscience, University of Connecticut Health Center Health Center, Farmington, CT
  • Footnotes
    Commercial Relationships Royce Mohan, University of Kentucky Research Foundation (P); Linda Cauley, None; Paola Bargagna-Mohan, UKY Research Foundation, US8283323B2 (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5975. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Royce Mohan, Linda Cauley, Paola Bargagna-Mohan; Type III Intermediate Filament Overexpression in the Genesis of Corneal Fibrosis. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5975. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: The type III intermediate filament (IF) vimentin is highly expressed in the cornea during fibrosis and was recently shown to be therapeutic target for corneal fibrosis (Bargagna-Mohan, JBC 2012). We used bone marrow transplantation (BMT) studies along with withaferin A, a vimentin/desmin-targeting small molecule probe, to investigate the myofibroblast-mediated genesis of corneal fibrosis.

Methods: Mice 129Svev wild type (WT) and 129 Svev vimentin-deficient (Vim KO) were subjected to corneal alkali injury with epithelial debridement. BMT from WT donors to Vim KO recipient mice and vice versa was performed and mice subjected to corneal injury. Mice were treated with vehicle or WFA at 2 mg/kg/d by intraperitoneal injection for different periods (1 week to 1 month), and corneas analyzed for opacity till 9 months post-injury using biomicroscopy and computer imaging colorimetric technique. Ocular tissues were analyzed using immunohistochemistry (IHC) and western blotting (WB) for fibrotic markers (vimentin, desmin, Skp2, alpha smooth muscle actin and p27Kip1)

Results: We previously reported that Vim KO mice recover from corneal injury with attenuated fibrosis, which was mimicked by WFA treatment in WT mice. Further improvement in corneal clarity by WFA in Vim KO was attributed to desmin downregulation. Our BMT experiments confirm that vimentin overexpression in corneal myofibroblasts (BM recipients from Vim KO) drive fibrosis, which was comparable with injured WT mice not subjected to BMT. This result was also corroborated in Vim KO mice (BM recipients from WT) that showed improved corneal clarity similar to injured Vim KO mice not subjected to BMT. In our longitudinal study, WFA treatment for 1 month with assessment at 9 months post-injury showed significant improvement in corneal clarity in WT recipients compared to vehicle treated mice (P<0.05). Vim KO mice that initiated with lower levels of corneal opacity at 1 month also maintained greater improvement after WFA treatment at 9 months (P<0.05). WB analysis and IHC results of early time points showed fibrotic corneas elaborating chronic myofibroblast expansion was associated with vimentin, desmin, alpha smooth muscle actin and Skp2 overexpression.

Conclusions: Collectively, our data advances the idea that myofibroblast-overexpression of type III IFs are critical targets for corneal fibrosis and could be pursued for development of new anti-fibrotic drugs.

Keywords: 484 cornea: stroma and keratocytes • 765 wound healing • 493 cytoskeleton  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.